Summary of head-to-head comparisons of patient risk classifications by the 21-gene Recurrence Score® (RS) assay and other genomic assays for early breast cancer

被引：38

作者：

Varga, Zsuzsanna ^{[1
]}

Sinn, Peter ^{[2
]}

Seidman, Andrew D. ^{[3
]}

机构：

[1] Univ Hosp Zurich, Inst Pathol & Mol Pathol, Schmelzbergstr 12, CH-8091 Zurich, Switzerland

[2] Heidelberg Univ, Inst Pathol, Gynecol Pathol, Heidelberg, Germany

[3] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

来源：

INTERNATIONAL JOURNAL OF CANCER | 2019年 / 145卷 / 04期

关键词：

multigene tests; breast cancer; risk score comparison; LATE DISTANT RECURRENCE; MOLECULAR GRADE INDEX; GENE-EXPRESSION; ONCOTYPE DX; PAM50; RISK; POSTMENOPAUSAL PATIENTS; INTRINSIC SUBTYPE; CLINICAL-OUTCOMES; DECISION-MAKING; RECEPTOR;

D O I：

10.1002/ijc.32139

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Many genomic assays that assess recurrence risk in early breast cancer (EBC) are prognostic, but they differ in risk group stratification, which can affect clinical utility. Prospective outcomes of >60 K patients treated based on the 21-gene assay results have shown that chemotherapy may be safely omitted in EBC patents with low Recurrence Score (RS) results (RS < 18). Because of its extensive validation and wide clinical use, the RS assay is a common comparator in head-to-head studies with other assays. Published/presented studies of the RS assay performed on the same tumor samples with Breast Cancer Index (BCI), EndoPredict (EP) or EP+ clinical features (EPclin), MammaPrint (MMP) and/or Prosigna (ROR) assays were reviewed. Study findings were summarized descriptively.

引用

页码：882 / 893

页数：12

共 59 条

[1] Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial
Albain, Kathy S.
Barlow, William E.
Shak, Steven
Hortobagyi, Gabriel N.
Livingston, Robert B.
Yeh, I-Tien
Ravdin, Peter
Bugarini, Roberto
Boehner, Frederick L.
Davidson, Nancy E.
Sledge, George W.
Winer, Eric P.
Hudis, Clifford
Ingle, James N.
Perez, Edith A.
Pritchard, Kathleen I.
Shepherd, Lois
Gralow, Julie R.
Yoshizawa, Carl
Allred, D. Craig
Osborne, C. Kent
Hayes, Daniel F.
[J]. LANCET ONCOLOGY, 2010, 11 (01) : 55 - 65
[2] Pooled analysis of prospective European studies assessing the impact of using the 21-gene Recurrence Score assay on clinical decision making in women with oestrogen receptor-positive, human epidermal growth factor receptor 2enegative early-stage breast cancer
Albanell, Joan
Svedman, Christer
Gligorov, Joseph
Holt, Simon D. H.
Bertelli, Gianfilippo
Blohmer, Jens-Uwe
Rouzier, Roman
Lluch, Ana
Eiermann, Wolfgang
[J]. EUROPEAN JOURNAL OF CANCER, 2016, 66 : 104 - 113
[3] A Prospective Comparison of the 21-Gene Recurrence Score and the PAM50-Based Prosigna in Estrogen Receptor-Positive Early-Stage Breast Cancer
Alvarado, Michael D.
Prasad, Che
Rothney, Megan
Cherbavaz, Diana B.
Sing, Amy P.
Baehner, Frederick L.
Svedman, Christer
Markopoulos, Christos J.
[J]. ADVANCES IN THERAPY, 2015, 32 (12) : 1237 - 1247
[4] Use of 70-gene signature to predict prognosis of patients with node-negative breast cancer: a prospective community-based feasibility study (RASTER)
不详
[J]. LANCET ONCOLOGY, 2007, 8 (12) : 1079 - 1087
[5] Comparing Breast Cancer Multiparameter Tests in the OPTIMA Prelim Trial: No Test Is More Equal Than the Others
Bartlett, John M. S.
Bayani, Jane
Marshall, Andrea
Dunn, Janet A.
Campbell, Amy
Cunningham, Carrie
Sobol, Monika S.
Hall, Peter S.
Poole, Christopher J.
Cameron, David A.
Earl, Helena M.
Rea, Daniel W.
Macpherson, Iain R.
Canney, Peter
Francis, Adele
McCabe, Christopher
Pinder, Sarah E.
Hughes-Davies, Luke
Makris, Andreas
Stein, Robert C.
[J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2016, 108 (09):
[6] MammaPrint versus EndoPredict: Poor correlation in disease recurrence risk classification of hormone receptor positive breast cancer
Boesl, Andreas
Spitzmueller, Andreas
Jasarevic, Zerina
Rauch, Stefanie
Jaeger, Silke
Offner, Felix
[J]. PLOS ONE, 2017, 12 (08):
[7] Comparison of EndoPredict and EPclin With Oncotype DX Recurrence Score for Prediction of Risk of Distant Recurrence After Endocrine Therapy
Buus, Richard
Sestak, Ivana
Kronenwett, Ralf
Denkert, Carsten
Dubsky, Peter
Krappmann, Kristin
Scheer, Marsel
Petry, Christoph
Cuzick, Jack
Dowsett, Mitch
[J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2016, 108 (11):
[8] Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer
Buyse, Marc
Loi, Sherene
van't Veer, Laura
Viale, Giuseppe
Delorenzi, Mauro
Glas, Annuska M.
d'Assignies, Mahasti Saghatchian
Bergh, Jonas
Lidereau, Rosette
Ellis, Paul
Harris, Adrian
Bogaerts, Jan
Therasse, Patrick
Floore, Arno
Amakrane, Mohamed
Piette, Fanny
Rutgers, Emiel
Sotiriou, Christos
Cardoso, Fatima
Piccart, Martine J.
[J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2006, 98 (17): : 1183 - 1192
[9] 70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer
Cardoso, F.
van't Veer, L. J.
Bogaerts, J.
Slaets, L.
Viale, G.
Delaloge, S.
Pierga, J. -Y.
Brain, E.
Causeret, S.
DeLorenzi, M.
Glas, A. M.
Golfinopoulos, V.
Goulioti, T.
Knox, S.
Matos, E.
Meulemans, B.
Neijenhuis, P. A.
Nitz, U.
Passalacqua, R.
Ravdin, P.
Rubio, I. T.
Saghatchian, M.
Smilde, T. J.
Sotiriou, C.
Stork, L.
Straehle, C.
Thomas, G.
Thompson, A. M.
van der Hoeven, J. M.
Vuylsteke, P.
Bernards, R.
Tryfonidis, K.
Rutgers, E.
Piccart, M.
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (08) : 717 - 729
[10] A 50-Gene Intrinsic Subtype Classifier for Prognosis and Prediction of Benefit from Adjuvant Tamoxifen
Chia, Stephen K.
Bramwell, Vivien H.
Tu, Dongsheng
Shepherd, Lois E.
Jiang, Shan
Vickery, Tammi
Mardis, Elaine
Leung, Samuel
Ung, Karen
Pritchard, Kathleen I.
Parker, Joel S.
Bernard, Philip S.
Perou, Charles M.
Ellis, Matthew J.
Nielsen, Torsten O.
[J]. CLINICAL CANCER RESEARCH, 2012, 18 (16) : 4465 - 4472

← 1 2 3 4 5 6 →